RBS2418 Clinical Trials (2026): 4 Studies for Advanced Cancer & Advanced Colorectal Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 RBS2418 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Advanced Cancer & Advanced Colorectal Cancer) and 534 total planned enrollment. 3 RBS2418 clinical trials are actively recruiting at 18 U.S. sites across 10 states. Most recent activity: NCT06824064 (Dec 2027).
Where to Participate: All RBS2418 Trial Sites in the U.S. (18 sites across 10 states)
Every actively recruiting RBS2418trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Honor Health Research Institute | Scottsdale85258 | NCT05270213 | Map |
| AZ | University of Arizona | Tucson85724 | NCT05270213 | Map |
| CA | Stanford Cancer Institute | Palo Alto94305 | NCT05270213 | Map |
| CA | UCLA Hematology/Oncology - Santa Monica | Santa Monica90404 | NCT05270213 | Map |
| DE | Christiana Care | Newark19718 | NCT06824064 | Map |
| DE | Christiana Care Health Services | Newark19713 | NCT05270213 | Map |
| KY | Norton Cancer Institute | Louisville40202 | NCT05270213 | Map |
| LA | Ochsner Clinic Foundation | New Orleans70121 | NCT05270213 | Map |
| MD | Johns Hopkins | Baltimore21218 | NCT07175441 | Map |
| MD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore21224 | NCT05270213 | Map |
| MD | American Oncology Partners of Maryland | Bethesda20817 | NCT05270213 | Map |
| NY | Ichan School of Medicine at Mount Sinai | New York10029 | NCT05270213 | Map |
| TN | Vanderbilt-Ingram Cancer Center | Nashville37235 | NCT05270213 | Map |
| TN | Vanderbilt-Ingram Cancer Center | Nashville37232 | NCT07175441 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT07175441 | Map |
| TX | START Dallas Fort Worth | Fort Worth76104 | NCT07175441 | Map |
| TX | Community Clinical Trials | Kingwood77339 | NCT06824064 | Map |
| VA | NEXT Virigina | Fairfax22031 | NCT05270213 | Map |
RBS2418 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | no longer available | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 2 | 2 | |
| N/A | 1 | 1 |
Recruiting RBS2418 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06824064 | VISTA-1Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 150 | Jan 2025 |
| NCT05270213 | Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | P1 | Advanced Cancer | 164 | Jul 2022 |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | P2 | Advanced Unresectable Hepatocellular Carcinoma | 220 | Apr 2026 |
RBS2418 clinical trials by indication
Advanced Unresectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07175441 | — | P2 | recruiting | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma |
Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06824064 | VISTA-1 | P2 | recruiting | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer |
Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05270213 | — | P1 | recruiting | Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors |
Expanded Access in Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05683470 | — | N/A | no longer available | Expanded Access RBS2418 Treatment |
RBS2418 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VISTA-1 | NCT06824064 | P2 | recruiting | Metastatic Colorectal Cancer | 150 | — |
All RBS2418 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06824064 | VISTA-1 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer | P2 | recruiting | 150 | Riboscience, LLC. | Jan 2025 |
| NCT05270213 | Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | P1 | recruiting | 164 | Riboscience, LLC. | Jul 2022 | |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | P2 | recruiting | 220 | Riboscience, LLC. | Apr 2026 | |
| NCT05683470 | Expanded Access RBS2418 Treatment | — | no longer available | 0 | Riboscience, LLC. | — |
RBS2418 clinical trials: frequently asked questions
- How many RBS2418 clinical trials are there?
- 4 RBS2418 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are RBS2418 clinical trials recruiting in 2026?
- Yes — 3 RBS2418 trials are actively recruiting in 2026, with 18 U.S. sites across 10 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is RBS2418 being studied for?
- RBS2418 is being studied for Advanced Cancer, Advanced Colorectal Cancer, Advanced Unresectable Hepatocellular Carcinoma, Expanded Access in Pancreatic Cancer, Metastatic Colorectal Cancer. The trials are grouped by indication on this page.
- What phase is RBS2418 in?
- RBS2418 clinical trials span 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors RBS2418 clinical trials?
- The lead sponsor across the most RBS2418 trials is Riboscience, LLC.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming RBS2418as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: